WO2020045765A1 - 클라미도모나스 변이주 및 이의 제조방법 - Google Patents
클라미도모나스 변이주 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2020045765A1 WO2020045765A1 PCT/KR2018/016518 KR2018016518W WO2020045765A1 WO 2020045765 A1 WO2020045765 A1 WO 2020045765A1 KR 2018016518 W KR2018016518 W KR 2018016518W WO 2020045765 A1 WO2020045765 A1 WO 2020045765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- mutant
- culture
- cultures
- chlamydomonas
- Prior art date
Links
- 241000195585 Chlamydomonas Species 0.000 title claims description 64
- 238000002360 preparation method Methods 0.000 title description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 100
- 229940043269 zeaxanthin Drugs 0.000 claims abstract description 68
- 239000001775 zeaxanthin Substances 0.000 claims abstract description 68
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims abstract description 67
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims abstract description 67
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims abstract description 67
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 67
- 235000010930 zeaxanthin Nutrition 0.000 claims abstract description 67
- 239000000049 pigment Substances 0.000 claims abstract description 59
- 229960005375 lutein Drugs 0.000 claims abstract description 34
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 33
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000001656 lutein Substances 0.000 claims abstract description 21
- 235000012680 lutein Nutrition 0.000 claims abstract description 20
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 49
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 241000899639 Reinhardtia Species 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 101150022366 ZEP gene Proteins 0.000 claims description 34
- 208000002780 macular degeneration Diseases 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 206010064571 Gene mutation Diseases 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 15
- 241000195597 Chlamydomonas reinhardtii Species 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 210000001525 retina Anatomy 0.000 claims description 9
- 230000006866 deterioration Effects 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000004262 retinal health Effects 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000643 adenine Drugs 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 abstract description 23
- 235000008210 xanthophylls Nutrition 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 235000006708 antioxidants Nutrition 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000036542 oxidative stress Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 108010031403 zeaxanthin epoxidase Proteins 0.000 description 30
- 239000002609 medium Substances 0.000 description 28
- 230000035772 mutation Effects 0.000 description 20
- 108091027544 Subgenomic mRNA Proteins 0.000 description 15
- 108091033409 CRISPR Proteins 0.000 description 12
- 238000003209 gene knockout Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 235000021466 carotenoid Nutrition 0.000 description 7
- 150000001747 carotenoids Chemical class 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 5
- 238000012350 deep sequencing Methods 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 230000029553 photosynthesis Effects 0.000 description 5
- 238000010672 photosynthesis Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108030000403 Lycopene epsilon-cyclases Proteins 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 239000003674 animal food additive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229930002868 chlorophyll a Natural products 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241001464837 Viridiplantae Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000004460 silage Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 101000683591 Homo sapiens Ras-responsive element-binding protein 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023544 Ras-responsive element-binding protein 1 Human genes 0.000 description 2
- 240000000785 Tagetes erecta Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001651 autotrophic effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229930002869 chlorophyll b Natural products 0.000 description 2
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010457 gene scissor Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000032821 Macular pigmentation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 101150094405 NAC23 gene Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 101150046339 fur gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- -1 green plants Chemical compound 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 210000001916 photosynthetic cell Anatomy 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P23/00—Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
Definitions
- the present invention relates to algae having a zeaxanthin production capacity, a method for producing the algae, and the use of the algae.
- Macular degeneration is a disease that causes vision impairment due to degeneration in the macular tissue, a nerve tissue located in the center of the inner retina of the eye.Most of the eye cells are collected in the macula and the image is formed at the center of the macula. Is in charge of. The most common causes of macular degeneration are age-related macular degeneration and are known to be associated with family history, race and smoking.
- Macular degeneration is largely divided into non-exudative (dry) and exudative (wet). About 80-90% of the macular degeneration is non-exudative macular degeneration. Non-exudative macular degeneration is progressing slowly and the symptoms worsen rarely, but there is no special treatment, such as health foods can be greatly helped to alleviate the symptoms and not worsen anymore. Exudative macular degeneration proceeds quite urgently and requires active treatment for vision preservation. If the boundary of the site of degeneration can be clearly understood, thermal laser photocoagulation, photodynamic therapy, antibody injection, vitrectomy, etc. may be performed, but there is no method or treatment for treating macular degeneration completely.
- Macular pigmentation reduces senile deterioration caused by the central part of the retina and prevents damage to retinal tissues caused by bright light.
- Representative examples include carotenoid-based oxycarotenoid pigments produced by oxygenation of carotenoids as xanthophyll (xanthophyll) and lutein or zeaxanthin as pigments belonging to xanthophylls.
- lutein is abundant in most green leafy vegetables, including marigold, but since zeaxanthin is a pigment produced by oxidative stress, its content is much smaller than that of lutein, making it difficult to use green plants as a raw material of zeaxanthin.
- Bacteria systems have been devised to replace green plant systems, but pigments from bacteria are ultimately unsuitable for use as food additives, and bacterial cultures and bioreactors are also very expensive to maintain.
- microalgae are attracting attention as photosynthetic cell plants that convert carbon dioxide into high value products such as biofuels, antioxidants, fatty acids and carotenoids.
- Microalgae have more carotenoid content than other sources, have high growth rate and productivity, no limitation of arable land, and short harvest cycle, which makes it very suitable for producing carotenoid pigments, but it is difficult to separate between pigments. There is still a need for research to selectively produce pigments.
- unmodified wild type microalgae are generally rich in lutein like green plants, but have low content of zeaxanthin and cannot produce zeaxanthin selectively under cultivation conditions. Not suitable for xanthine pigment production. Therefore, there is a need for a new aspect of approach for industrial production of zeaxanthin using microalgae.
- An object of the present invention is to provide a method for effective production of zeaxanthin and zeaxanthin through the same, and specifically to provide a microalgae having excellent zeaxanthin production ability and its use for efficient and improved production of zeaxanthin. .
- the present inventors developed a mutant strain with improved biological properties from wild-type or existing microalgae using mutations other than genetic recombination methods, and identified an optimal method for producing zeaxanthin using the same.
- the present invention was completed.
- the mutant strain of the present invention has a markedly improved zeaxanthin production ability in the xanthophyll pigment, lutein is not produced, and thus only the zeaxanthin can be easily obtained in the process of extracting and separating the pigment after culturing the algae.
- the present invention provides adenine (A) between the 816th and 817th bases in the ZEP gene sequence of Chlamydomonas reinhardtii represented by SEQ ID NO: 1; A nucleotide sequence represented by SEQ ID NO: 3; Or ZEP gene mutation into which the nucleotide sequence represented by SEQ ID NO: 5 is inserted; And a nucleotide sequence represented by SEQ ID NO: 9 between 599 and 600 bases in the LCYE gene sequence of Chlamydomonas reinhardtii represented by SEQ ID NO: 2; Or Chlamydomonas reinhardtii mutants comprising the LCYE gene mutation inserted nucleotide sequence represented by SEQ ID NO: 11 is provided.
- A adenine
- the mutant strain may be zeaxanthin-producing ability while not producing lutein.
- the present invention also provides a culture of the mutant strains.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And it provides a pigment composition comprising one or more selected from the group consisting of the mutant strain or the extract of the culture.
- the pigment may be zeaxanthin.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And eye health enhancement or maintenance comprising at least one selected from the group consisting of extracts of the mutant strains or cultures; Macular degeneration prevention or improvement; Preventing or improving deterioration of the eye; Improving or preventing damage to the retina; Inhibiting aging of the eye; Maintaining retinal health; Reduced risk of developing macular degeneration; Or it provides a composition for preventing or improving macular degeneration.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And it provides a food or food additive composition comprising at least one selected from the group consisting of the mutant strain or the extract of the culture.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And it provides a feed or feed additive composition comprising at least one selected from the group consisting of the mutant strain or the extract of the culture.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And it provides a composition for injection comprising one or more selected from the group consisting of the mutant strain or the extract of the culture.
- the present invention is the above variant strain; Its culture; Dried products of the mutant strains or cultures; And enhancing or maintaining eye health at least one selected from the group consisting of extracts of the mutant strains or cultures; Macular degeneration prevention or improvement; Preventing or improving deterioration of the eye; Improving or preventing damage to the retina; Anti-aging; Maintaining retinal health; Reduced risk of developing macular degeneration; Or provide a dietary supplement for preventing or improving macular degeneration.
- the present invention also provides a pigment production method comprising culturing the mutant strain.
- the present invention provides a method for producing a raw material of food or feed comprising culturing the mutant strain.
- a mutation position capable of simultaneously knocking out a ZEP gene and an LCYE gene without introducing foreign DNA in the microalga Chlamydomonas reinhardtia was developed, and thus a new mutant strain including simultaneous knockout was developed.
- it has a significant increase in the production of industrially useful pigment zeaxanthin and at the same time does not produce lutein, so that the step of separating / purifying zeaxanthin and lutein Without knowing that it can efficiently produce zeaxanthin on a commercial scale, it is expected to have a great economic effect in terms of industrial production of zeaxanthin using microalgae.
- Figure 1 shows an overall description of the method for producing ZEP and LCYE genetically corrected Chlamydomonas mutant strains according to one embodiment of the invention.
- Figures 2a, 2b and 2c shows ZEP gene information (2a, SEQ ID NO: 4) of the Chlamydomonas Reinhardthia mutant strain ⁇ Z1, ZEP gene information (2b, SEQ ID NO: 6) and Chlamydo of the Chlamydomonas Reinhardtia variant strain ⁇ Z2, respectively.
- the ZEP gene information (2c, SEQ ID NO: 8) of the Monas Reinhardtia variant strain ⁇ Z3 is shown.
- 3A and 3B show mutations in the ZEP gene induced by DNA-free RGEN RNPs
- 3a RGEN-transfected cells and wild type mutation (insertion and deletion; indel) frequency for each sgRNA targeted Measured by Targeted deep sequencing. Indel frequency was measured to about 0.46%.
- 3b Representative mutant DNA sequence (RGEN3), ie TCCGGCGAACGCACCTGGATGGG, obtained from the third most efficient sgRNA observed in the targeted deep sequencing analysis of a.
- Targeted deep sequencing analysis revealed various indel patterns identified at the target sequence, 3nt upstream of the PAM sequence. 20-bp target sequences are underlined and PAM sequences are shown in bold.
- FIG. 4 shows the results of confirming the target DNA sequence change of the actual ZEP gene position by Sanger sequencing in three ZEP mutants generated by DNA-free RGEN RNPs [a: wildtype, b : ZEP mutant 1 ( ⁇ Z1), c: ZEP mutant 2 ( ⁇ Z2) d. ZEP mutant 3 ( ⁇ Z3)].
- FIG. 5 shows the Cas9 protein sequence (SEQ ID NO: 15) used in one embodiment of the present invention.
- FIGS. 6a, 6b and 6c are photographs showing the morphological characteristics of Chlamydomonas Reinhardtia cw15 wild type bird, Chlamydomonas Reinhardtia mutants ⁇ Z1, ⁇ Z2, ⁇ Z3
- 6a Hundreds of colonies for studying ZEP gene knockout Of chlorophyll fluorescence (Chl) fluorescence
- 6b Photo incubated in a colony state in solid TAP medium containing agar
- Figure 7 shows the sequence information (SEQ ID NO: 2) of the LCYE (Lycopene epsilon cyclase) gene of wild type Chlamydomonas .
- FIGS. 8A and 8B show information about the LCYE gene (SEQ ID NOs: 10, 8a) and the dZL2 variant LCYE gene (SEQ ID NOs: 12, 8b) of Chlamydomonas reinhardti, respectively .
- the underlined sequences in red refer to the sequences inserted into the variant strains respectively.
- Figure 9 shows the cell photographs in solid TAP medium of wild type Chlamydomonas Reinhardti cw15, ZEP 1 mutant, dZA1 mutant, dZA2 mutant.
- Figure 10a and 10b shows the results of the pigment analysis according to an embodiment of the present invention
- 10a is a comparison of the pigment profile of Chlamydomonas Reinhard ti cw15 wild type algae, ZEP Mutant 1, mutant dZL1 and mutant dZL2
- 10b is a HPLC analysis graph comparing the pigment profiles of Chlamydomonas Reinhardtia mutants ⁇ Z1, ⁇ Z2, ⁇ Z3: lutein and zeaxanthin content of chlorophyll a (Chl a): neo-neoxanthin ), vio-violaxanthin, An-antheraxanthin, lut-lutein, zea-zeaxanthin, chl a-chlorophyll a, chl b: chlorophyll b ( chlorophyll b).
- Figure 10c is a graph confirming the zeaxanthin and lutein production characteristics and production of Chlamydomonas Reinhardti cw15 wild type alga, ZEP Mutant 1, mutant dZL1 and mutant dZL2 according to an embodiment of the present invention.
- Figure 11 shows an autotrophic culture vessel according to an embodiment of the present invention.
- Figure 12 shows a mixed nutrient culture vessel according to an embodiment of the present invention.
- the present invention Chlamydomonas Reinhardti reinhardtii ) on mutant strains .
- Chlamydomonas Reinhard tiai of the present invention is a unicellular green alga (Chlorophyta) is a eukaryotes distributed in various environments, such as fresh water, the ocean, and has a doubling time of 6 to 8 hours. It is also one of the most widely used microalgal model systems, which can be produced in bioreactors.
- Variant of the present invention using RGNE RNPs, CRISPR gene scissors technology but not the general mutation treatment ZEP ( Zeaxanthin It can be produced by knocking out the epoxidase gene and the LCYE gene Lycopene epsilon cyclase .
- the variant strain of the present invention ZEP ( Zeaxanthin epoxidase ) gene and LCYE ( Lycopene epsilon cyclase ) may include mutations at specific positions of the gene.
- the mutant of the present invention is defined by the ZEP (Zeaxanthin epoxidase ) gene and LCYE ( Lycopene epsilon Variation of cyclase ) genes can be specified through location, and the production of mutant strains from wild type Chlamydomonas reinhardtia microalgae is possible.
- mutation indicates that the base sequence is changed by the insertion, deletion, or substitution of the base in the original base sequence.
- insertion variation is generated by inserting a portion of the base between the original base sequence. Meaning the variation, the number of the base to be inserted may be different depending on the variation, and is not limited accordingly.
- Variant of the present invention may include an insertion mutation in which some bases are inserted between the 816th base and the 817th base in the ZEP gene sequence of Chlamydomonas reinhardtii, which is represented by SEQ ID NO: 1.
- the ZEP gene can be knocked out.
- the present invention provides adenine (A) between the 816th base and the 817th base in the ZEP gene sequence (SEQ ID NO: 1) of wild-type Chlamydomonas reinhardtii cw15; A nucleotide sequence represented by SEQ ID NO: 3; Or it may include a ZEP gene mutation in which the nucleotide sequence represented by SEQ ID NO: 5 is inserted, it was confirmed that the ZEP gene is effectively knocked out in each of the mutant strains.
- mutant strains of the present invention comprise adenine (A) between the 816th base and the 817th base in the ZEP gene sequence (SEQ ID NO: 1); A nucleotide sequence represented by SEQ ID NO: 3; Or a ZEP gene mutation into which the nucleotide sequence represented by SEQ ID NO: 5 is inserted.
- the variant strain of the present invention may include a mutation in which some bases are inserted between the 599th and 600th base in the LCYE gene sequence of Chlamydomonas reinhardtii represented by SEQ ID NO: 2, It is possible to knock out the LCYE gene.
- a variant strain wherein 94 or 1870 bases are inserted between 599th and 600th bases in the LCYE gene sequence (SEQ ID NO: 2) of wild-type Chlamydomonas reinhardtii cw15. It was confirmed that the LCYE gene was knocked out effectively in each of the mutant strains .
- the present invention has a very large technical feature in that a mutation strain in which the LCYE gene is knocked out can be obtained when an insertion mutation occurs between the 599th base and the 600th base in the LCYE gene sequence of SEQ ID NO: 2.
- the mutant strain is a nucleotide sequence represented by SEQ ID NO: 9 between the 599th base and the 600th base in the LCYE gene sequence (SEQ ID NO: 2); Alternatively, the nucleotide sequence represented by SEQ ID NO: 11 may include an LCYE gene mutation inserted.
- the mutant strain of the present invention is a nucleotide sequence represented by column number 9 between the 599th base and the 600th base in the LCYE gene sequence (SEQ ID NO: 2); Alternatively, the nucleotide sequence represented by SEQ ID NO: 11 may include an LCYE gene mutation inserted.
- the variant strains of the present invention are ZEP and LCYE It may be to include genetic variation simultaneously.
- a nucleotide sequence represented by SEQ ID NO: 9 between 599 and 600 bases in the LCYE gene sequence of Chlamydomonas reinhardtii represented by SEQ ID NO: 2; Or it may be a Chlamydomonas Reinhardtia mutant strain containing the LCYE gene mutation inserted into the base sequence represented by SEQ ID NO: 11.
- mutant strain of the present invention is a ZEP gene mutation represented by SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8; And SEQ ID NO: 8; Or LCYE gene mutation represented by SEQ ID NO: 10.
- the ZEP gene mutation of SEQ ID NO: 8; And a ZEP / LCYE double gene knockout variant comprising the LCYE gene mutation represented by SEQ ID NO: 10 was designated dZL1 (double ZEP / LCYE mutant 1), and the ZEP gene mutation of SEQ ID NO: 8; And a double gene knockout mutant comprising the LCYE gene mutation represented by SEQ ID NO: 12 was designated dZL2 (double ZEP / LCYE mutant 2).
- the inventors also found that Chlamydomonas among the selected mutants.
- Hard Rain tiahyi the deposit of the double ZEP / LCYE mutant 1 (dZL1 ) mutant August 21, 2018 Date of the Korea Research Institute of Bioscience and Biotechnology Biological Resource Center (KCTC), was given an accession number of KCTC 13626BP.
- both strains were effectively ZEP / LCYE double gene knockout was confirmed to have a significantly improved zeaxanthin production without lutein production.
- the mutant strains of the present invention have significantly improved zeaxanthin production capacity compared to the chlamydomonas reinhardtia cw15 wild type without the conventional zeaxanthin production ability, and in particular, it does not produce lutein, and thus can only selectively produce zeaxanthin. It has the advantage that it can be used effectively in the production of zeaxanthin.
- the mutant strains of the present invention are viable in dim light and specifically can be cultured under luminous conditions in the range of 10 to 2,000 ⁇ mol photons / m 2 s. Photosynthesis is not possible at complete darkness where the mutant strain is below the weak light condition, and cells may be damaged by light stress at too high light conditions.
- culturing the mutant strain of the present invention under the above conditions there is an advantage of having a high growth rate, while having a high zeaxanthin content in the mutant strain.
- the mutant strains of the present invention can grow appropriately in a growth environment (brightness conditions, temperature conditions, medium, etc.) capable of culturing conventional Chlamydomonas reinhardtia algae.
- a growth environment (brightness conditions, temperature conditions, medium, etc.) capable of culturing conventional Chlamydomonas reinhardtia algae.
- it has an excellent ability of accumulating zeaxanthin even at low brightness, and thus can be used industrially as a zeaxanthin pigment-producing microorganism due to its excellent ability to produce zeaxanthin, and the density in the colony is relatively low even under high brightness compared to other algae.
- the pigment production efficiency due to photosynthesis in a single cell has an excellent effect.
- the Chlamydomonas Reinhardtia wild type produced almost no zeaxanthin, but the mutant strains of the present invention contained about 30 times higher zeaxanthin content than the wild type and do not produce lutein, which is very suitable for the production of zeaxanthin. Do.
- the mutant strain of the present invention can be cultured according to the general conditions of the general Chlamydomonas reinhardtia, and specifically, a culture medium capable of culturing algae under weak luminous conditions can be used.
- a culture medium capable of culturing algae under weak luminous conditions
- the nutrient substance required by the microorganism to be cultured that is, the culture medium
- the medium may also be referred to as an incubator or a culture medium, and includes a natural medium, a synthetic medium, or a selective medium.
- the Chlamydomonas Reinhardtia mutants can be cultured according to a conventional culture method.
- the mutant strain of the present invention may be cultured in a photosynthetic medium, HS medium or TAP medium, and may further include a carbon source.
- a photosynthetic medium for example, it may be cultured in a photosynthetic medium, HS medium or TAP medium, and may further include a carbon source.
- the mutant strain of the present invention has excellent zeaxanthin production capacity.
- the pH of the culture medium is not particularly limited as long as the range of Chlamydomonas reinhardti can survive and grow, for example, at pH 6 or more, specifically, pH 6 to pH 9, and may be pH 7.0 or more and less than pH 8.0. It can have an optimal growth rate.
- Variant strains of the present invention can be prepared by introducing the RGEN RNPs directly into the target sequence in the ZEP gene and LCYE gene using the Christopher gene shear technique.
- Chlamydomonas Reinhardtia mutants of the present invention can accumulate high amounts of zeaxanthin pigment in cells, and thus, zeaxanthin obtained from the mutant strain of the present invention or its culture can be effectively used as a raw material for food, feed, medicine, etc. have.
- the present invention relates to a culture of said Chlamydomonas reinhardtia variant strain.
- the term "culture” refers to a medium in which a specific microorganism is cultured, that is, a medium after culture, and the culture comprises a residue containing the Chlamydomonas Reinhardtia mutants or the mutants removed after culturing them. It includes everything.
- the culture is meant to include both the concentrate of the culture or the dried product of the culture in which the culture medium is concentrated, dried and the like after the culture.
- the culture may include by-products thereof, and the formulation is not limited, and may be, for example, liquid or solid.
- the medium may contain a nutritional substance required by the microorganism to be cultured, that is, the culture medium in order to cultivate the characteristic microorganism, and may be mixed with an additional substance for a special purpose.
- the medium may also be referred to as an incubator or a culture medium, and is a concept including all natural, synthetic, or selective media.
- the pH of the medium may be in the range in which the Chlamydomonas Reinhardtia mutants can be grown, for example pH 6 or more, preferably pH 6 to pH 9.
- the present invention also relates to a composition
- a composition comprising one or more selected from the group consisting of Chlamydomonas reinhardtia mutants, cultures of the algae, dried products of the mutants or cultures and extracts thereof.
- Variation of the present invention has a characteristic of generating a xanthophyll-based pigment containing zeaxanthin to accumulate in the body, in this aspect the composition may be a pigment composition, or may be a zeaxanthin pigment composition.
- the pigment composition may be used as a raw material for food or feed, may be used as an oral administration or an oral administration formulation, and specifically, may be used as a preparation for oral, ocular or injection administration. Therefore, the pigment composition or the xanthophyll pigment composition containing the composition or extract may be a composition for oral administration or injection in that it can be supplied orally in food, medicine or feed.
- compositions for oral administration include powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions, and the like, oral formulations formulated using methods known in the art. Can be.
- oral formulations can obtain tablets or tablets of sugars by combining the active ingredients with solid excipients, milling them, adding suitable auxiliaries and then processing them into granule mixtures.
- excipients examples include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch, cellulose, including starch, corn starch, wheat starch, rice starch and potato starch, etc. Fillers such as cellulose, gelatin, polyvinylpyrrolidone, and the like, including methyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose, and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant.
- the composition can be used for the purpose of promoting the health of humans and animals.
- the mutant strain of the present invention has a high ability to produce zeaxanthin and can selectively produce only zeaxanthin without producing lutein, and thus can be used as a raw material for foods, health functional foods, feeds, or medicines containing zeaxanthin as an active ingredient. have.
- the present invention is a variant of the present invention; Its culture; Dried products of the mutant strains or cultures; And eye health enhancement or maintenance comprising at least one selected from the group consisting of extracts of the mutant strains or cultures; Macular degeneration prevention or improvement; Preventing or improving deterioration of the eye; Improving or preventing damage to the retina; Inhibiting aging of the eye; Maintaining retinal health; Reduced risk of developing macular degeneration; Or it relates to a composition for preventing or improving macular degeneration.
- the composition may be added to food or feed to achieve a particular purpose use, and in this aspect may be a food composition, a composition for food additives, a feed composition or a composition for feed additives.
- the body may be maintained or strengthened by zeaxanthin produced by Chlamydomonas reinhardtia mutants and accumulated in cells.
- the zeaxanthin may be used as a macular pigment to prevent or improve degeneration of the macula, and is effective in preventing or improving eye diseases associated with macular degeneration.
- the zeaxanthin may be used to enhance or maintain eye health; Macular degeneration prevention or improvement; Preventing or improving deterioration of the eye; Improving or preventing damage to the retina; Anti-aging; Maintaining retinal health; Reduced risk of developing macular degeneration; Or since there is an effect of preventing or improving macular degeneration, the feed or food composition may be used for the prevention or amelioration of the symptoms, or for the effect.
- additives is included if all the ingredients are added to the food or feed in addition to the main ingredients, specific examples of food and drug safety added in the active ingredient or processed foods having a functional function in food or feed for coloring, preservation, etc. It may be a food additive as defined by the department.
- the food may be a health functional food. More specifically, it may be a health functional food for eye health.
- Feed composition in the present invention may be prepared in the form of fermented feed, compound feed, pellet form and silage (silage) and the like.
- the fermented feed includes Chlamydomonas reinhardtia mutant strain of the present invention, the dry strain of the mutant strain, the culture of the mutant strain and extracts thereof, and may be prepared by additionally including various microorganisms or enzymes.
- the combination feed may be prepared by mixing, including various kinds of general feed and the mutant strain of the present invention, the dry cells of the mutant strain, the culture of the algae and extracts thereof.
- Pellet feed can be prepared by formulating the fermented feed or blended feed into a pellet machine.
- Silage may be prepared by mixing a cultivated feed and Chlamydomonas Reinhardtia mutants, dry cells of the mutants, cultures of the mutants and / or extracts thereof, but the use of the composition of the present invention is not limited thereto. .
- the composition may be mixed with carriers and flavoring agents commonly used in the food or pharmaceutical field to form tablets, troches, capsules, elixirs, syrups, powders. It may be prepared and administered in the form of a suspension or granules.
- binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents and the like can be used as the carrier.
- the mode of administration may be oral, parenteral or application, but preferably oral administration.
- the dosage may be appropriately selected depending on the absorbency, inactivation rate and excretion rate of the active ingredient in the body, age, sex, condition, etc. of the recipient.
- the pH of the composition can be easily changed in accordance with the manufacturing conditions, such as drugs, foods, etc. that the composition is used.
- the composition is 0.001 to 99.99% by weight, based on the total weight of the composition of any one selected from the group consisting of Chlamydomonas Reinhardtia mutant strain, culture of the mutant strain, dried product of the mutant strain or culture and extract of the mutant strain or culture.
- Chlamydomonas Reinhardtia mutants may be included in the composition in its own or in dried form, and the culture of the algae may be included in the composition in concentrated or dried form.
- the dried means the dried form of the algae or its culture, it may be in the form of powder prepared by lyophilization and the like.
- the extract is meant to be obtained by extracting from Chlamydomonas Reinhardtia mutant strain of the present invention, its culture solution or dried product thereof, obtained by crushing the extract using a solvent or the like, Chlamydomonas Reinhardtia mutant strain of the present invention It includes.
- the pigment accumulated in the cells of Chlamydomonas reinhardtia variant of the present invention may be extracted and separated by physical or chemical methods.
- the extraction process may be carried out by a conventional method, for example, by adding an extraction solvent and homogenizing, pulverizing the cells can be extracted the target pigment.
- the algae crushed material is removed by centrifugation, and the extraction solvent can be removed by distillation under reduced pressure. It may also further comprise a conventional purification process. Since the pigment has a property of being insoluble in water, it can be more easily extracted from the algae of the present invention.
- Chlamydomonas Reinhardtia mutant of the present invention has excellent production capacity of xanthophyll, especially zeaxanthin at low brightness
- the composition comprising the mutant and its by-products can improve the body activity, maintain body function and prevent degradation
- the xanthophyll pigment is known to have macular degeneration inhibitory effect, antioxidant, anticancer effect, etc.
- the composition of the present invention is for maintaining physical health, and in particular, preventing maintenance and deterioration of body functions related to the xanthophyll pigment. Or it can be used as a raw material contained in food, health food, medicine or feed for the purpose of improvement.
- another object of the present invention is to provide a method for producing a pigment using the Chlamydomonas rain hard tia mutant of the present invention.
- the pigment production method may include culturing Chlamydomonas reinhardtia mutants of the present invention.
- another object of the present invention is to provide a raw material production method of food or feed comprising culturing the Chlamydomonas Reinhardtia mutants of the present invention.
- the pigment may be zeaxanthin.
- the mutant strain of the present invention it is possible to produce a high content of zeaxanthin without producing lutein, and thus there is a great advantage in that it can be effectively used for selective production of zeaxanthin.
- Chlamydomonas Reinhardtia mutant of the present invention can increase the amount of zeaxanthin accumulation in the algae cultured, and do not produce lutein, so it is not necessary to go through the step for separating / purifying only zeaxanthin, which is used industrially It can be effectively used to supply zeaxanthin as a raw material.
- the production method may further include, after the culturing step, separating the Chlamydomonas Reinhardtia mutants of the present invention from the culture.
- the separated algae may be subjected to further processing steps including drying.
- the production method may further include extracting a pigment from the Chlamydomonas rain hardy mutant strain of the present invention, the culture of the mutant strain, the concentrate of the culture or the dried product of the culture.
- the culture may be performed in a medium of pH 6.0 to 8.0 conditions. It may also be carried out under light conditions, in particular light conditions in the range from 10 to 2,000 ⁇ mol photons / m 2 s.
- Chlamydomonas reinhardtia variant of the present invention it is excellent in pigment production ability even at low brightness, and can increase the content of zeaxanthin in the body, and thus it is possible to achieve excellent zeaxanthin accumulation without administering high-brightness energy. Can be effectively used.
- the extraction may be performed by a conventional method for extracting a pigment from a microorganism, and examples thereof include an enzyme method, an ultrasonic extraction method, a mechanical extraction method, and the like.
- the production method may further include a concentration step of increasing the content of algae after the cultivation, and a drying step of drying by further reducing the moisture of the algae after the concentration step.
- concentration step or the drying step is not necessarily required, and in general, it may be performed using a concentration and drying method or machine commonly used in the field to which the present invention belongs.
- the production method may be performed by further including a purification step after the extraction step, which may be performed by a conventional purification method in the art.
- Xanthophyll prepared through the concentration or drying step may be used as a raw material for food, health functional food, cosmetics or drugs.
- the xanthophyll production method may be performed by employing another method within a range that does not impair the effects of the present invention.
- mutant strains and compositions may be mutatis mutandis also for the production method of the present invention.
- Clomidomonas algae was carried out according to the following medium and culture conditions, unless otherwise specified.
- culture was performed by supplying 5% CO 2 in a minimum medium of HS medium.
- the autoclave was autoclaved, using a cell in an active growth stage (growth stage) to start the growth by making a concentration of 10 6 cells / mL in the culture.
- the culture vessel was supplied with air from the bottom using a glass column (column) as shown in FIG. 11, and light was emitted using a fluorescent lamp at a brightness of 200 uE from both sides.
- acetic acid was added in TAP medium.
- the autoclave was autoclaved and sterilized, and growth was started by making a concentration of 10 6 cells / mL in a culture medium using cells in an active growth stage.
- the culture vessel was incubated in a large volume using a glass flask or bottle as shown in FIG. 12 and stirred using a magnetic bar.
- the light of 70uE was given by using a fluorescent lamp.
- sgRNAs Five sgRNAs were carefully designed within half of the coding sequence region of the ZEP gene which differed from any other target sites by 3 nucleotides (nt) in the whole genome and had an out-of-frame score higher than 66.
- 'CDS (coding sequence) position' means the relative position of a cleavage point in an RNA transcript. + Of Direction is the sequence of RGEN in the same direction as the target sequence, that is, the same sequence is the sequence of RGEN, and-is the sequence of complement complementary relationship, which is the reverse of the target sequence, i.e., the sequence which is associated with the target sequence. Means.
- 'Out-of-frame score' refers to the possibility of frameshift-induced deletions that occur when broken double-stranded DNA is repaired by the microhomology-mediated end joining (MMEJ) pathway.
- MMEJ microhomology-mediated end joining
- '# Of target-off sites' refers to the number of mismatched sequences throughout the entire genome. Linking the remaining sgRNA sequence (Gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc, SEQ ID NO: 18) to the target sequence shows the entire sgRNA.
- Cas9 protein was prepared through purification by expressing a recombinant Cas9 protein (recombinant Cas9 protein) using E. coli .
- the wild-type Chlamydomonas reinhardtia cw15 mt (CC-4349) used in the experiment was obtained through the Chlamydomonas Resource Center (www.chlamycollection.org) [http://www.chlamycollection.org/product/cc-4349- cw15-mt-goodenough-330a /].
- Chlamydomonas cells were incubated in a 50 ml flask at 25 ° C. using TAP medium of Table 2 to provide light using a fluorescent lamp at a light intensity of 70 uE and shaking at 90 rpm. The concentration of cells was measured using a spectrophotometer, and cells of about 0.3 to 0.5 at OD 750 were actively cultured.
- RNPs complex 200 ⁇ g of Cas9 protein (FIG. 5, SEQ ID NO: 15) was mixed with 140 ⁇ g of sgRNA (SEQ ID NO: 16) in nuclease-free water and incubated at room temperature for 10 minutes.
- the bound RNPs complex was used with a Biorad Gene Pulser Xcell TM Electroporation System in a 4 mm electroporation cuvette with 50 ⁇ 10 4 wild-type Chlamydomonas Reinhardtia cw15 mt (CC-4349) cells. (Voltage 600V, Capacity 50uF), transformed by electric shock, incubated in dark for 12 hours, gDNA was extracted, and analyzed by targeted deep sequencing. Dilution was carried out on a TAP agar plate to obtain a single colony.
- FIG. 3A and 3B show the results of confirming the mutation of the ZEP gene induced by RGEN-RNPs by target deep sequencing.
- a single colony induced by the third most efficient sgRNA (0.456%) was isolated to identify mutations in the target gene.
- Figure 3b is a result of the target in-depth sequencing, after the transformation experiment using the RNP to collect all the cells and gDNA extracted by analyzing all the mutations occurring in the DNA strands of the target site for all cells analyzed the pattern and frequency (frequency Can be seen.
- FIG. 3B shows the patterns of mutations actually identified at the target site through target depth sequencing, since large size changes, such as insertions of 42 bp or more, are difficult to find with the principle of target depth sequencing, thus actually obtaining a single colony. (single colony) may vary.
- the red circle in FIG. 6A indicates the putative ZEP knockout mutant grown on TAP agar medium under light (50 ⁇ mol photons / m 2 s) conditions.
- NPQ / 4 images were measured by Imaging PAM (Walz).
- Single cell colonies of wild type (WT) and ⁇ ZEP mutant strains were grown on at least agar medium under light (50 ⁇ mol photons / m 2 s) conditions (FIGS. 6A and 6B).
- Three variants ( ⁇ Z1 , ⁇ Z2 , ⁇ Z3 ) with increased macula pigment content were selected from the colonies thus identified, and the target DNA sequence change of the actual ZEP gene position in three ZEP mutants generated by RGEN RNPs. was confirmed by Sanger sequencing (Figs. 2a, 2b and 2c).
- Chlamydomonas rain hard tiahyi ZEP mutation 1 ( ⁇ Z1) to (Chlamydomonas reinhardtii ZEP mutant 1 ( ⁇ Z1)) in the mutant Korea Research Institute of Bioscience and Biotechnology Biological Resource Center (KCTC) was named 2017 It was deposited on March 22, 2011 and was granted accession number KCTC 13230BP.
- mutant Z1 was used for double gene correction.
- Example 3 From Chlamydomonas Crisper Genetic scissors technology ( CRISPR - Cas9 RNP With) LCYE ( Lycopene epsilon cyclase A) gene knockout Chlamydomonas Mutant Manufacturing
- sgRNAs used Cas-Designer (www.rgenome.net) to construct four sgRNAs to induce microhomology-driven frame shift mutations.
- Cas-Designer www.rgenome.net
- Four sgRNAs designed to target the LCYE gene are shown in Table 4 below (see Table 3 for the meaning of each item; target locations in Table 4 describe base positions based on CDS sequences).
- RNPs complex 200 ⁇ g of Cas9 protein (SEQ ID NO: 15) and 140 ⁇ g of sgRNA (SEQ ID NO: 17) were mixed in nuclease-free water and incubated at room temperature for 10 minutes.
- the combined RNPs complex was prepared with a Biorad Gene Pulser Xcell TM Electroporation System in a 4 mm electroporation cuvette with 1 ⁇ g hygromycin resistant gene cassette and 50 ⁇ 10 4 Chlamydomonas cells. By transfection (Voltage 600V, Capacity 50uF), incubated for 12 hours, and then all were plated on TAP agar plates with hygromycin added to single colony. Got.
- Figure 7 shows the gene information and target sequence of the LCYE of wild-type Chlamydomonas Reinhardtia birds, the dZL1 and dZL2 mutants selected through the genetic correction has the genetic information of Figures 8a and 8b respectively. Sanger sequencing) confirmed.
- mutant dZL1 was named Chlamydomonas Reinhardti double ZEP / LCYE mutant 1 (dZL1), which was deposited on August 21, 2018 at the Korea Institute of Bioscience and Biotechnology (KCTC). Accession number KCTC 13626BP was assigned.
- the total flow rate of the solvent was 1.2 mL / min, and uniformly decreased Tris of pH 8.0 to 14%, acetonitrile to 84% to 0%, respectively, from 0 minutes to 15 minutes, Methanol and ethyl acetate started at 2% and increased by 68% and 32%, respectively, by the 15th minute.
- the solvent ratio is then maintained for 3 minutes (15th to 18th minutes), then for 1 minute (18th to 19th minutes), return to the rate at which each solvent is started and then for the remaining 6 minutes. Postruns were maintained as they were.
- FIGS. 10A and 10B are ZEP It is the result of the analysis of the pigment
- FIG. 10a the pigment profile of the cells was analyzed using HPLC
- FIG. 10b the amounts of lutein and zeaxanthin per chlorophyll a (Chl a) were compared with wild type.
- the mutant of ZEP / LCYE double gene knockout showed no lutein content, unlike the Z1 mutant strain . It can be seen that it has a very different bacteriological properties from the mutant strains containing only mutations.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (15)
- 서열번호 1로 표시되는 클라미도모나스 레인하드티아이(Chlamydomonas reinhardtii)의 ZEP 유전자 서열에서 816번째 염기와 817번째 염기 사이에 아데닌(A); 서열번호 3으로 표시되는 염기서열; 또는 서열번호 5로 표시되는 염기서열이 삽입된 ZEP 유전자 변이; 및서열번호 2로 표시되는 클라미도모나스 레인하드티아이(Chlamydomonas reinhardtii)의 LCYE 유전자 서열에서 599번째 염기와 600번째 염기 사이에 서열번호 9로 표시되는 염기서열; 또는 서열번호 11로 표시되는 염기서열이 삽입된 LCYE 유전자 변이를 포함하는 클라미도모나스 레인하드티아이(Chlamydomonas reinhardtii) 변이주.
- 제1항에 있어서,서열번호 4, 서열번호 6, 또는 서열번호 8로 표시되는 ZEP 변이 유전자; 및서열번호 10; 또는 서열번호 12으로 표시되는 LCYE 변이 유전자를 포함하는 클라미도모나스 레인하드티아이 변이주.
- 제1항 또는 제2항에 있어서,상기 변이주는 지아잔틴(zeaxanthin) 생성능을 가지면서, 루테인(lutein)을 생산하지 않는 것을 특징으로하는, 클라미도모나스 레인하드티아이 변이주.
- 제1항에 있어서,서열번호 4로 표시되는 ZEP 변이 유전자; 및서열번호 10으로 표시되는 LCYE 변이 유전자를 포함하는 클라미도모나스 레인하드티아이 변이주.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주의 배양물,
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 포함하는 색소 조성물.
- 제6항에 있어서,상기 색소는 지아잔틴(zeaxanthin)를 포함하는 것 인, 색소 조성물.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 포함하는 눈 건강 강화 또는 유지; 황반변성 예방 또는 개선; 눈의 기능 저하 예방 또는 개선; 망막의 손상 개선 또는 예방; 눈의 노화 억제; 망막 건강 유지; 황반변성 발병 위험 감소; 또는 시력감퇴 예방 또는 개선용 조성물.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 포함하는 식품용 또는 식품첨가제용 조성물.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 포함하는 사료용 또는 사료첨가제용 조성물.
- 제 1 항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 포함하는 주사제용 조성물.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주; 이의 배양물; 상기 변이주 또는 배양물의 건조물; 및 상기 변이주 또는 배양물의 추출물로 이루어진 군에서 선택된 하나 이상을 눈 건강 강화 또는 유지; 황반변성 예방 또는 개선; 눈의 기능 저하 예방 또는 개선; 망막의 손상 개선 또는 예방; 눈의 노화 억제; 망막 건강 유지; 황반변성 발병 위험 감소; 또는 시력감퇴 예방 또는 개선을 위한 건강기능식품.
- 제1항 내지 제4항 중 어느 한 항에 따른 변이주를 배양하는 것을 포함하는 색소 생산방법.
- 제13항에 있어서,상기 변이주, 상기 변이주의 배양물, 상기 배양물의 농축물 또는 상기 배양물의 건조물로부터 색소를 분리하는 것;을 포함하는 색소 생산방법.
- 제 1 항 내지 제4항 중 어느 한 항에 따른 변이주를 배양하는 것;을 포함하는 식품 또는 사료의 원료 생산방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180102306A KR101981935B1 (ko) | 2018-08-29 | 2018-08-29 | 클라미도모나스 변이주 및 이의 제조방법 |
KR10-2018-0102306 | 2018-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020045765A1 true WO2020045765A1 (ko) | 2020-03-05 |
Family
ID=66656766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/016518 WO2020045765A1 (ko) | 2018-08-29 | 2018-12-21 | 클라미도모나스 변이주 및 이의 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101981935B1 (ko) |
WO (1) | WO2020045765A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102445369B1 (ko) * | 2019-12-03 | 2022-09-21 | 한양대학교 산학협력단 | 미세조류로부터 기능성 오일을 추출하는 방법 및 기능성 오일을 포함하는 유화액 |
KR102442480B1 (ko) | 2020-01-02 | 2022-09-13 | 한양대학교 산학협력단 | 클라미도모나스 변이주 배양용 조성물 및 이의 배양방법 |
KR102603612B1 (ko) | 2023-07-14 | 2023-11-17 | 한국해양과학기술원 | 아스타잔틴 및 루테인 생산능을 가지는 클라미도모나스속 kiost-2 균주 및 이의 배양방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170121688A (ko) * | 2016-04-22 | 2017-11-02 | 한양대학교 산학협력단 | Rgen rnp를 이용하여 개발된 클라미도모나스 변이주 및 이를 이용한 색소 생산방법 |
-
2018
- 2018-08-29 KR KR1020180102306A patent/KR101981935B1/ko active IP Right Grant
- 2018-12-21 WO PCT/KR2018/016518 patent/WO2020045765A1/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170121688A (ko) * | 2016-04-22 | 2017-11-02 | 한양대학교 산학협력단 | Rgen rnp를 이용하여 개발된 클라미도모나스 변이주 및 이를 이용한 색소 생산방법 |
Non-Patent Citations (4)
Title |
---|
DATABASE NCBI, GenBank 24 May 2016 (2016-05-24), XP055695895, Database accession no. KX077950.1 * |
DATABASE NCBI, GenBank 29 August 2000 (2000-08-29), XP055695899, Database accession no. AF295371.1 * |
DATABASE NCBI, GenBank 29 August 2017 (2017-08-29), XP055695901, Database accession no. XM 001696477.1 * |
DATABASE NCBI, GenBank 4 April 2003 (2003-04-04), XP055695886, Database accession no. AY211267.1 * |
Also Published As
Publication number | Publication date |
---|---|
KR101981935B1 (ko) | 2019-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10973246B2 (en) | Chlamydomonas mutants produced using RGEN RNP and method for preparing pigment using the same | |
WO2020045765A1 (ko) | 클라미도모나스 변이주 및 이의 제조방법 | |
US20210198680A1 (en) | Heterotrophic Production Methods for Microbial Biomass and Bioproducts | |
KR102445369B1 (ko) | 미세조류로부터 기능성 오일을 추출하는 방법 및 기능성 오일을 포함하는 유화액 | |
WO2017209510A1 (ko) | 두나리엘라 변이주 및 이를 이용한 색소 생산 방법 | |
WO2022124590A1 (ko) | 신규한 스키조키트리움 속 균주 및 이를 이용한 다중불포화지방산 생산방법 | |
US20130309719A1 (en) | Heterotrophic microbial production of xanthophyll pigments | |
WO2020145685A1 (ko) | 클라미도모나스 변이주 및 이의 용도 | |
CN1880309A (zh) | 新化合物、新菌株、及应用该菌株生产该新化合物的方法 | |
WO2021019409A1 (en) | Astaxanthin over-producing strains of phaffia rhodozyma | |
KR102163257B1 (ko) | 비올라잔틴 생산성이 높은 신규 미세조류 | |
WO2017183936A1 (ko) | Rgen rnp를 이용한 미세조류의 교정 방법 | |
WO2024039163A1 (ko) | 고함량의 단백질, 항산화 색소 및 오메가-3 지방산을 포함하는 바이오매스를생산하는 신규한 스키조키트리움 속 균주 및 이의 용도 | |
WO2013151363A1 (ko) | 신규 분리한 바실러스 리체니포미스 및 이를 이용한 프로바이오틱스 | |
WO2022250389A1 (ko) | 신규 두나리엘라 살리나 및 이의 용도 | |
WO2022158814A1 (ko) | 제아잔틴 및 루테인의 생산성이 높은 신규 미세조류 | |
JP3320417B2 (ja) | アスタキサンチン含有動物プランクトン | |
KR102603612B1 (ko) | 아스타잔틴 및 루테인 생산능을 가지는 클라미도모나스속 kiost-2 균주 및 이의 배양방법 | |
KR20090040122A (ko) | 아스타잔틴 추출이 용이한 파피아 로도지마 돌연변이주 및그 추출법 | |
WO2023038443A1 (ko) | 장수풍뎅이 누디바이러스 배양용 배지 조성물 및 이를 이용한 장수풍뎅이 누디바이러스의 배양 방법 | |
EP3839056A1 (en) | Astaxanthin over-producing strains of phaffia rhodozyma | |
WO2019092421A1 (en) | Microorganism | |
CN1544619A (zh) | 利用三裂叶野葛毛状根生产葛根素的方法 | |
JPS643878B2 (ko) | ||
CN1007267B (zh) | 抗生素6270的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18932219 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18932219 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/03/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18932219 Country of ref document: EP Kind code of ref document: A1 |